ORIGINAL
Análisis coste-efectividad de celecoxib frente a antiinflamatorios no esteroideos no selectivos en el tratamiento de la artrosis en España: una perspectiva actual
Cost-effectiveness analysis of celecoxib versus non-selective non-steroidal anti-inflammatory drug therapy for the treatment of osteoarthritis in Spain: A current perspective
a Máster en Evaluación Sanitaria y Acceso al Mercado (Farmacoeconomía), Universidad Carlos III, Getafe, Madrid, España
b Servicio de Cirugía Ortopédica y Traumatología, Hospital General Universitario Gregorio Marañón, Madrid, España
c UGC Limonar , Málaga, España
d Pharmacoeconomics & Outcomes Research Iberia, Pozuelo de Alarcón, Madrid, España
e Departamento de Farmacoeconomía e Investigación de Resultados en Salud, Pfizer SLU, Alcobendas, Madrid, España
Leído
11451
Vecesse ha leído el artículo
1628
Total PDF
9823
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 12 | 163 | 39 | 202 |
| 2025 11 | 151 | 21 | 172 |
| 2025 10 | 199 | 22 | 221 |
| 2025 9 | 139 | 26 | 165 |
| 2025 8 | 150 | 28 | 178 |
| 2025 7 | 154 | 16 | 170 |
| 2025 6 | 214 | 8 | 222 |
| 2025 5 | 188 | 11 | 199 |
| 2025 4 | 276 | 6 | 282 |
| 2025 3 | 170 | 14 | 184 |
| 2025 2 | 186 | 14 | 200 |
| 2025 1 | 160 | 7 | 167 |
| 2024 12 | 218 | 16 | 234 |
| 2024 11 | 143 | 12 | 155 |
| 2024 10 | 129 | 10 | 139 |
| 2024 9 | 148 | 20 | 168 |
| 2024 8 | 139 | 12 | 151 |
| 2024 7 | 133 | 5 | 138 |
| 2024 6 | 119 | 9 | 128 |
| 2024 5 | 143 | 7 | 150 |
| 2024 4 | 116 | 16 | 132 |
| 2024 3 | 107 | 11 | 118 |
| 2024 2 | 128 | 7 | 135 |
| 2024 1 | 122 | 10 | 132 |
| 2023 12 | 135 | 15 | 150 |
| 2023 11 | 215 | 6 | 221 |
| 2023 10 | 228 | 11 | 239 |
| 2023 9 | 141 | 4 | 145 |
| 2023 8 | 84 | 5 | 89 |
| 2023 7 | 93 | 7 | 100 |
| 2023 6 | 104 | 2 | 106 |
| 2023 5 | 95 | 54 | 149 |
| 2023 4 | 103 | 7 | 110 |
| 2023 3 | 92 | 9 | 101 |
| 2023 2 | 92 | 8 | 100 |
| 2022 1 | 92 | 12 | 104 |
| 2022 12 | 81 | 12 | 93 |
| 2022 11 | 134 | 24 | 158 |
| 2022 10 | 135 | 34 | 169 |
| 2022 9 | 90 | 21 | 111 |
| 2022 8 | 86 | 15 | 101 |
| 2022 7 | 83 | 21 | 104 |
| 2022 6 | 93 | 26 | 119 |
| 2022 5 | 71 | 8 | 79 |
| 2022 4 | 59 | 15 | 74 |
| 2022 3 | 65 | 16 | 81 |
| 2022 2 | 70 | 13 | 83 |
| 2021 1 | 123 | 18 | 141 |
| 2021 12 | 59 | 19 | 78 |
| 2021 11 | 75 | 23 | 98 |
| 2021 10 | 54 | 12 | 66 |
| 2021 9 | 45 | 22 | 67 |
| 2021 8 | 59 | 10 | 69 |
| 2021 7 | 41 | 32 | 73 |
| 2021 6 | 51 | 11 | 62 |
| 2021 5 | 45 | 21 | 66 |
| 2021 4 | 113 | 30 | 143 |
| 2021 3 | 85 | 19 | 104 |
| 2021 2 | 47 | 10 | 57 |
| 2020 1 | 56 | 20 | 76 |
| 2020 12 | 42 | 23 | 65 |
| 2020 11 | 68 | 16 | 84 |
| 2020 10 | 30 | 14 | 44 |
| 2020 9 | 65 | 12 | 77 |
| 2020 8 | 101 | 20 | 121 |
| 2020 7 | 43 | 18 | 61 |
| 2020 6 | 48 | 27 | 75 |
| 2020 5 | 67 | 21 | 88 |
| 2020 4 | 51 | 16 | 67 |
| 2020 3 | 58 | 12 | 70 |
| 2020 2 | 46 | 11 | 57 |
| 2020 1 | 56 | 8 | 64 |
| 2019 12 | 80 | 18 | 98 |
| 2019 11 | 63 | 16 | 79 |
| 2019 10 | 47 | 18 | 65 |
| 2019 9 | 68 | 11 | 79 |
| 2019 8 | 28 | 6 | 34 |
| 2019 7 | 39 | 40 | 79 |
| 2019 6 | 114 | 31 | 145 |
| 2019 5 | 238 | 35 | 273 |
| 2019 4 | 83 | 34 | 117 |
| 2019 3 | 30 | 15 | 45 |
| 2019 2 | 38 | 19 | 57 |
| 2019 1 | 32 | 11 | 43 |
| 2018 12 | 25 | 19 | 44 |
| 2018 11 | 32 | 15 | 47 |
| 2018 10 | 109 | 6 | 115 |
| 2018 9 | 59 | 13 | 72 |
| 2018 8 | 29 | 16 | 45 |
| 2018 7 | 18 | 3 | 21 |
| 2018 6 | 38 | 10 | 48 |
| 2018 5 | 33 | 8 | 41 |
| 2018 4 | 34 | 8 | 42 |
| 2018 3 | 30 | 3 | 33 |
| 2018 2 | 19 | 2 | 21 |
| 2018 1 | 13 | 5 | 18 |
| 2017 12 | 15 | 1 | 16 |
| 2017 11 | 26 | 6 | 32 |
| 2017 10 | 18 | 2 | 20 |
| 2017 9 | 18 | 6 | 24 |
| 2017 8 | 17 | 4 | 21 |
| 2017 7 | 21 | 0 | 21 |
| 2017 6 | 37 | 11 | 48 |
| 2017 5 | 34 | 12 | 46 |
| 2017 4 | 23 | 1 | 24 |
| 2017 3 | 33 | 11 | 44 |
| 2017 2 | 106 | 9 | 115 |
| 2016 1 | 33 | 1 | 34 |
| 2016 12 | 42 | 5 | 47 |
| 2016 11 | 53 | 5 | 58 |
| 2016 10 | 99 | 13 | 112 |
| 2016 9 | 61 | 11 | 72 |
| 2016 8 | 44 | 8 | 52 |
| 2016 7 | 43 | 12 | 55 |
| 2016 6 | 2 | 1 | 3 |
| 2016 5 | 35 | 10 | 45 |
Mostrar todo
